These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 7086847)

  • 1. Inhibitors of adenosine deaminase. Studies in combining high-affinity enzyme-binding structural units. erythro-1,6-Dihydro-6-(hydroxymethyl)-9-(2-hydroxy-3-nonyl)purine and erythro-9-(2-hydroxy-3-nonyl)purine.
    Woo PW; Baker DC
    J Med Chem; 1982 May; 25(5):603-5. PubMed ID: 7086847
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adenosine deaminase inhibitors: synthesis and structure-activity relationships of imidazole analogues of erythro-9-(2-hydroxy-3-nonyl)adenine.
    Cristalli G; Eleuteri A; Franchetti P; Grifantini M; Vittori S; Lupidi G
    J Med Chem; 1991 Mar; 34(3):1187-92. PubMed ID: 2002459
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adenosine deaminase inhibitors. Synthesis of deaza analogues of erythro-9-(2-hydroxy-3-nonyl)adenine.
    Antonini I; Cristalli G; Franchetti P; Grifantini M; Martelli S; Lupidi G; Riva F
    J Med Chem; 1984 Mar; 27(3):274-8. PubMed ID: 6699873
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adenosine deaminase inhibitors. Conversion of a single chiral synthon into erythro- and threo-9-(2-hydroxy-3-nonyl)adenines.
    Bastian G; Bessodes M; Panzica RP; Abushanab E; Chen SF; Stoeckler JD; Parks RE
    J Med Chem; 1981 Dec; 24(12):1383-5. PubMed ID: 7310814
    [No Abstract]   [Full Text] [Related]  

  • 5. Effect of erythro-9-(2-hydroxy-3-nonyl) adenine on purine and pyrimidine metabolism in the human peripheral lymphocyte during the early phases of phytohemagglutinin-mediated blastogenesis.
    Skupp S; Vugrek G; Ayvazian JH
    Biochem Pharmacol; 1979 Nov; 28(22):3323-31. PubMed ID: 526339
    [No Abstract]   [Full Text] [Related]  

  • 6. Effects of the chiral isomers of erythro- and threo-9-(2-hydroxy-3-nonyl)adenine on purine metabolism in sarcoma 180 cells.
    Chen SF; Stoeckler JD; Choi HS; Burgess FW; Marcaccio EJ; Steen PA; Berman SF; Parks RE; Panzica RP; Abushanab E
    Biochem Pharmacol; 1982 Dec; 31(24):3955-60. PubMed ID: 7159473
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of chirality in erythro-9-(2-hydroxy-3-nonyl) adenine (EHNA) on adenosine deaminase inhibition.
    Bessodes M; Bastian G; Abushanab E; Panzica RP; Berman SF; Marcaccio EJ; Chen SF; Stoeckler JD; Parks RE
    Biochem Pharmacol; 1982 Mar; 31(5):879-82. PubMed ID: 7082355
    [No Abstract]   [Full Text] [Related]  

  • 8. Adenosine deaminase inhibitors. Synthesis and biological activity of deaza analogues of erythro-9-(2-hydroxy-3-nonyl)adenine.
    Cristalli G; Franchetti P; Grifantini M; Vittori S; Lupidi G; Riva F; Bordoni T; Geroni C; Verini MA
    J Med Chem; 1988 Feb; 31(2):390-3. PubMed ID: 3339608
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibition of brain adenosine deaminase by 2'-deoxycoformycin and erythro-9-(2-hydroxy-3-nonyl) adenine.
    Skolnick P; Nimitkitpaisan Y; Stalvey L; Daly JW
    J Neurochem; 1978 Jun; 30(6):1479-82. PubMed ID: 670988
    [No Abstract]   [Full Text] [Related]  

  • 10. Inhibition of adenosine deaminase from several sources by deaza derivatives of adenosine and EHNA.
    Lupidi G; Cristalli G; Marmocchi F; Riva F; Grifantini M
    J Enzyme Inhib; 1985; 1(1):67-75. PubMed ID: 3916912
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition of human T-cell rosette formation by the adenosine deaminase inhibitor erythro-9-(2-hydroxy-3-nonyl) adenine hydrochloride (EHNA).
    Lum CT; Schmidtke JR; Sutherland DE; Najarian JS
    Clin Immunol Immunopathol; 1978 Jul; 10(3):258-61. PubMed ID: 307473
    [No Abstract]   [Full Text] [Related]  

  • 12. Pharmacokinetics of inhibition of adenosine deaminase by erythro-9-(2-hydroxy-3-nonyl)adenine in CBA mice.
    Lambe CU; Nelson DJ
    Biochem Pharmacol; 1982 Feb; 31(4):535-9. PubMed ID: 7066021
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adenosine deaminase inhibitors. Synthesis and biological evaluation of putative metabolites of (+)-erythro-9-(2S-hydroxy-3R-nonyl)adenine.
    Vargeese C; Sarma MS; Pragnacharyulu PV; Abushanab E; Li SY; Stoeckler JD
    J Med Chem; 1994 Oct; 37(22):3844-9. PubMed ID: 7966142
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Erythro-9-(2-hydroxy-3-nonyl) Adenine alone and in combination with 9-beta-D-arabinofuranosyladenine in treatment of systemic herpesvirus infections in mice.
    Shannon WM; Arnett G; Schabel FM; North TW; Cohen SS
    Antimicrob Agents Chemother; 1980 Oct; 18(4):598-603. PubMed ID: 6255863
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The adenosine deaminase inhibitor erythro-9-[2-hydroxyl-3-nonyl]-adenine decreases intestinal permeability and protects against experimental sepsis: a prospective, randomised laboratory investigation.
    Kayhan N; Funke B; Conzelmann LO; Winkler H; Hofer S; Steppan J; Schmidt H; Bardenheuer H; Vahl CF; Weigand MA
    Crit Care; 2008; 12(5):R125. PubMed ID: 18847498
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sedative and electroencephalographic actions of erythro-9-(2-hydroxy-3-nonyl)-adenine (EHNA): relationship to inhibition of brain adenosine deaminase.
    Mendelson WB; Kuruvilla A; Watlington T; Goehl K; Paul SM; Skolnick P
    Psychopharmacology (Berl); 1983; 79(2-3):126-9. PubMed ID: 6405420
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibition of PHA and NaI04 mitogenesis by the adenosine deaminase inhibitors erythro-9-(2-hydroxy-3-nonyl) adenine (EHNA) and 2-deoxycoformycin (2-dCF).
    Lum CT; Sutherland DE; Najarian JS
    Clin Immunol Immunopathol; 1979 Apr; 12(4):453-9. PubMed ID: 222523
    [No Abstract]   [Full Text] [Related]  

  • 18. Comparison of the activity of 2'-deoxycoformycin and erythro-9-(2-hydroxy-3-nonyl)adenine in vivo.
    Plunkett W; Alexander L; Chubb S; Loo TL
    Biochem Pharmacol; 1979; 28(2):201-6. PubMed ID: 426835
    [No Abstract]   [Full Text] [Related]  

  • 19. The protonated form of 1-N6-etheno-[erythro-9-(2-hydroxy-3-nonyl)] adenine is identified at the active site of adenosine deaminase.
    Caiolfa VR; Gill D; Parola AH
    FEBS Lett; 1990 Jan; 260(1):19-22. PubMed ID: 2153576
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adenosine deaminase inhibitors. Synthesis and biological evaluation of C1' and nor-C1' derivatives of (+)-erythro-9-(2(S)-hydroxy-3(R)-nonyl)adenine.
    Harriman GC; Poirot AF; Abushanab E; Midgett RM; Stoeckler JD
    J Med Chem; 1992 Oct; 35(22):4180-4. PubMed ID: 1433220
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.